BioCardia director buys 109,200 shares in market
BioCardia, Inc. director Simon H. Stertzer reported open‑market purchases of the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioCardia, Inc. director Simon H. Stertzer reported open‑market purchases of the company’s common stock. On June 22, he bought 70,200 shares at a reported weighted average price of $0.92 per share, in multiple trades ranging from $0.90 to $0.97 per share.
On June 23, he bought an additional 39,000 shares at a reported weighted average price of $1.00 per share, in trades ranging from $1.00 to $1.01 per share. After these transactions, his direct holdings rose to 166,338 shares, and the filing also lists several indirect holdings through family trusts and LLCs, including positions such as 591,054 shares held by Stertzer Holdings LLC.
Insider Trade Summary
Net Buyer: 109,200 shares
Net Buy
6 txns
Insider
STERTZER SIMON H
Role
Director
Bought
109,200 shs ($104K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 39,000 | $1.00 | $39K |
| Purchase | Common Stock | 70,200 | $0.92 | $65K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 166,338 shares (Direct);
Common Stock — 657,137 shares (Indirect, See Footnote)
Footnotes (6)
- F1. This transaction was executed in multiple trades ranging from $0.90 to $0.97 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
- F2. This transaction was executed in multiple trades ranging from $1.00 to $1.01 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.
- F3. These shares are held by the Stertzer Family Trust, of which the Reporting Person and his spouse are co-trustees.
- F4. These shares are held by Windrock Enterprises L.L.C., of which the Reporting Person and his spouse are the sole members and managers.
- F5. These shares are held by the Stertzer Gamma Trust, of which the Reporting Person is the grantor.
- F6. These shares are held by Stertzer Holdings LLC, and the Reporting Person may be deemed to have beneficial ownership of such shares.
Key Figures
Open-market buy 1: 70,200 shares at $0.92/share
Open-market buy 2: 39,000 shares at $1.00/share
Total shares bought: 109,200 shares
+5 more
8 metrics
Open-market buy 1
70,200 shares at $0.92/share
Common Stock purchase on June 22, 2026 (weighted average price)
Open-market buy 2
39,000 shares at $1.00/share
Common Stock purchase on June 23, 2026 (weighted average price)
Total shares bought
109,200 shares
Net buy shares across reported open-market purchases
Direct holdings after trades
166,338 shares
Common Stock directly owned after June 23, 2026
Stertzer Holdings LLC position
591,054 shares
Indirect Common Stock holdings via Stertzer Holdings LLC
Stertzer Family Trust position
59,204 shares
Indirect Common Stock holdings via Stertzer Family Trust
Windrock Enterprises position
6,102 shares
Indirect Common Stock holdings via Windrock Enterprises L.L.C.
Stertzer Gamma Trust position
777 shares
Indirect Common Stock holdings via Stertzer Gamma Trust
Key Terms
open-market purchase, weighted average per share sales price, beneficial ownership, co-trustees, +1 more
5 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
beneficial ownership financial
"the Reporting Person may be deemed to have beneficial ownership of such shares."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
co-trustees financial
"These shares are held by the Stertzer Family Trust, of which the Reporting Person and his spouse are co-trustees."
grantor financial
"These shares are held by the Stertzer Gamma Trust, of which the Reporting Person is the grantor."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BioCardia (BCDA) director Simon H. Stertzer do in this Form 4?
Simon H. Stertzer reported open-market purchases of BioCardia common stock. He bought shares on June 22 and June 23, increasing his direct ownership and disclosing additional indirect holdings through family trusts and LLCs associated with him.
What are Simon H. Stertzer’s direct BioCardia (BCDA) holdings after these transactions?
Following the reported open-market purchases, Simon H. Stertzer’s direct holdings of BioCardia common stock total 166,338 shares. This figure reflects the position reported as directly owned by him after the June 22 and June 23 transactions.
What indirect BioCardia (BCDA) holdings are reported for Simon H. Stertzer?
The filing lists several indirect holdings, including shares held by the Stertzer Family Trust, Windrock Enterprises L.L.C., the Stertzer Gamma Trust, and Stertzer Holdings LLC, with individual positions such as 591,054 shares reported for Stertzer Holdings LLC.
Does this BioCardia (BCDA) Form 4 show any derivative or option exercises?
No derivative or option exercises are reported. The filing shows common stock transactions only, with two open-market purchases and several entries that reflect indirect holdings without derivative securities listed in the derivative transaction summary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
